Spots Global Cancer Trial Database for Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
Official Title: A Phase I Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
Study ID: NCT00625768
Interventions
Study Description
Brief Summary: To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of AS1409 in single and repeated doses.
Detailed Description: * To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose (MTD) of AS1409 in single and repeated doses. * To determine biological responses to AS1409, including interferon-γ and IP-10 circulating concentrations. * To determine preliminary pharmacokinetics of AS1409. * To determine the immunogenicity of AS1409 * To explore the anti-tumour activity of AS1409.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Auckland Medical School, Auckland, , New Zealand
Waikato DHB, Hamilton, , New Zealand
Guys Hospital, London, , United Kingdom
Charing Cross Hospital, London, , United Kingdom
Contact Details
Name: James Spicer, MD
Affiliation: Kings College School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
